At what age should a healthy adult receive the initial pneumococcal polysaccharide vaccine (PPS 23)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PPSV23 (Pneumovax) Recommended at Age 65 for Healthy Adults

For a healthy adult without chronic medical conditions or immunocompromising conditions, the initial PPSV23 (Pneumovax) is recommended at age 65 years. 1

Key Recommendations by Age and Health Status

Healthy Adults Under Age 65

  • No pneumococcal vaccination is recommended for healthy adults aged 19-64 years without chronic medical conditions 1
  • This means a truly healthy adult waits until age 65 to receive their first pneumococcal vaccine

Adults Age 65 and Older (Healthy)

  • All adults aged ≥65 years should receive 1 dose of PPSV23, regardless of prior vaccination history 1
  • PCV13 is no longer routinely recommended for healthy adults ≥65 years; instead, it is based on shared clinical decision-making between patient and provider 1
  • If PCV13 is given first (after shared decision-making), PPSV23 should follow ≥1 year later 1

Important Exception: Adults with Chronic Conditions (Ages 19-64)

Adults aged 19-64 years with chronic medical conditions should receive pneumococcal vaccination before age 65. These conditions include:

  • Chronic heart disease (congestive heart failure, cardiomyopathies)
  • Chronic lung disease (COPD, emphysema, asthma)
  • Diabetes mellitus
  • Chronic liver disease
  • Alcoholism
  • Cigarette smoking 1

For these patients, vaccination begins at the time of diagnosis with either PCV20, PCV21, or PCV15 followed by PPSV23 2, 3

High-Risk Immunocompromised Patients (Any Age ≥19)

Adults with immunocompromising conditions, CSF leaks, or cochlear implants should receive:

  • PCV13/PCV15/PCV20/PCV21 first, followed by PPSV23 at specified intervals
  • This applies regardless of age, including those under 65 1, 2

Clinical Pearls and Common Pitfalls

Pitfall #1: Vaccinating healthy adults before age 65

  • There is no indication for PPSV23 in healthy adults under 65 without risk factors
  • Providers often mistakenly vaccinate at age 50 or 60, which is not guideline-concordant for healthy individuals

Pitfall #2: Revaccination timing

  • If a patient received PPSV23 before age 65 (due to chronic conditions), they need one additional dose at age ≥65 years, provided ≥5 years have elapsed since the previous PPSV23 dose 1
  • No additional doses are recommended after the dose given at age ≥65 years 1

Pitfall #3: Confusion about PCV13

  • As of 2019, PCV13 is no longer routinely recommended for all adults ≥65 years 1
  • It is now based on shared clinical decision-making for healthy older adults
  • PCV13 remains recommended for those with immunocompromising conditions, CSF leaks, or cochlear implants 1

Updated Vaccine Options (2023-2024)

Newer conjugate vaccines (PCV15, PCV20, PCV21) are now available and may be used instead of the older PCV13/PPSV23 combination in certain scenarios 2, 3. However, for healthy adults reaching age 65, PPSV23 alone remains the standard recommendation unless shared decision-making leads to PCV use first.

References

Related Questions

Can a 58-year-old woman who has never received a pneumococcal vaccine be given the 23-valent pneumococcal polysaccharide vaccine (PPSV23)?
Can a 62-year-old adult receive a pneumococcal vaccine (PCV13 and PPSV23)?
What are the recommended Canadian pneumococcal vaccination schedules for infants, children, adults (including those 19‑64 with chronic conditions or immunocompromise) and adults aged 65 years and older?
What is the duration of protection provided by the pneumococcal (pneumonia) vaccine, specifically the pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV), in adults 65 years and older?
In a 61-year-old male receiving his first pneumococcal (PNA) vaccine, when should the second dose be given?
What are the clinical manifestations of heart failure in adults, and how are natriuretic peptides utilized in its diagnosis and management?
Should I discontinue Linzess (linaclotide) 72 mg before starting GoLYTELY bowel preparation for colonoscopy, and what is the proper timing schedule?
How should a patient with cardiorenal syndrome, chronic kidney disease (eGFR 30–45 mL/min), and diuretic resistance to maximal loop diuretics be managed?
What is the appropriate empiric antibiotic regimen for a patient with moderate-risk pneumonia on a tracheostomy tube in the ICU?
Which empiric antipseudomonal β‑lactam antibiotic is safe (does not lower seizure threshold) for an epileptic ICU patient with pneumonia?
In a patient presenting with acute dyspnea, how can I differentiate pulmonary edema from chronic obstructive pulmonary disease (COPD) with pulmonary hypertension, and what initial management steps should be taken?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.